The primary efficacy endpoint was the rate of pregnancies conceived “on-drug,” reported as the Pearl Index (PI). “On-drug” pregnancies were defined as those with dates of conception on or after the date of first dose of DSG/EE, but no more than 7 days after the last DSG/EE or EE-only tablet was taken (7-day rule). If the conception date was unknown, the date of the last dose was used to estimate the participant’s exposure in the efficacy analysis. Pregnancy rates were also evaluated using the 2-day rule of on-drug pregnancies as required by the European Medicine Agency [12]. In this analysis, pregnancies were considered on-drug if the date of conception was on or after the date of DSG/EE initiation and up to and including 2 days after the last DSG/EE or EE-only pill.